1.89
1.89 (0%)
As of Dec 16, 2022
Kineta, Inc. [YMTX]
Source:
Company Overview
Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance.
| Country | United States |
| Headquarters | seattle, washington |
| Phone Number | ( 206 ) 378-0400 |
| Industry | manufacturing |
| CEO | Shawn Iadonato |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-13.5 |
| Net Income | $-17.1 |
| Net Cash | $-5.2 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -303.3% |
| Profit as % of Stockholder Equity | 144.4% |
Management Effectiveness
| Return on Equity | 144.4% |
| Return on Assets | -1,681.8% |
| Turnover Ratio | |
| EBITA | $-13.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1 |
| Total Liabilities | $12.9 |
| Operating Cash Flow | $-11.6 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $6.3 |
